Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
ASCO 2024
Questions discussed in this category
What are your top takeaways from ASCO GI 2024?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...
1 Answer available
What are your top takeaways from ASCO GU 2024?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical prac...
4 Answers available
19234
19042
Papers discussed in this category
N Engl J Med,
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
The Lancet. Oncology, 2023 Sep 12
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Related Topics
Medical Oncology
Radiation Oncology
Genitourinary Cancers
Gastrointestinal Cancers